Mizuho Securities adjusts price target for intra-cellular therapies to $72 from $75, maintains buy rating







Newswires MT 2022

All the latest from INTRA-CELLULAR THERAPIES, INC.
11:40 a.m. Mizuho Securities adjusts price target for intra-cellular therapies to $72 from $75, maintains..

MT

10/08 Needham adjusts price target for intra-cellular therapies to $67 from $65, maintains buy rate..

MT

10/08 Goldman Sachs lowers price target for intra-cellular therapies to $64 from $71, maintains..

MT

09/08 INTRACELLULAR THERAPIES : ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES ..

COULD

09/08 TRANSCRIPTION : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, August 09, 2022

THIS

09/08 Intra-cellular therapies net loss widens in second quarter, revenue climbs

MT

09/08 INTRA-CELLULAR THERAPIES, INC. MANAGEMENT REPORT AND ANALYSIS OF FINANCIAL CONDITIONS..

QA

09/08 INTRA-CELLULAR : Overview of Q2 results

QA

09/08 INTRA-CELLULAR THERAPIES, INC. : Results of operations and financial situation, other even..

QA

09/08 Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Co..

QA

INTRA-CELLULAR THERAPIES, INC. Analyst Recommendations

2022 sales 239M

Net income 2022 -302M

Net cash 2022 549M

PER 2022 ratio -18.4x
2022 return
Capitalization 5,588 million
5,588 million
EV / Sales 2022 21.1x
EV / Sales 2023 12.5x
# of employees 512
Floating 97.6%

Chart INTRA-CELLULAR THERAPIES, INC.


Duration :

Period :




Intra-Cellular Therapies, Inc. Technical Analysis Chart |  MarketScreener

Technical Analysis Trends INTRA-CELLULAR THERAPIES, INC.

Short term Middle term Long term
Tendencies Neutral Neutral Bullish



Evolution of the income statement

Sale

To buy

Medium consensus TO BUY
Number of analysts 14
Last closing price $59.19
Average target price $70.31
Average Spread / Target 18.8%


Comments are closed.